Parth Mehrotra Sells 41,999 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 41,999 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $22.86, for a total transaction of $960,097.14. Following the completion of the transaction, the chief executive officer directly owned 343,795 shares of the company’s stock, valued at approximately $7,859,153.70. The trade was a 10.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Parth Mehrotra also recently made the following trade(s):

• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total transaction of $496,336.00.

Privia Health Group Stock Performance

Shares of PRVA traded down $0.83 during trading hours on Tuesday, reaching $22.47. The stock had a trading volume of 1,025,433 shares, compared to its average volume of 813,068. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The stock has a market capitalization of $2.78 billion, a PE ratio of 132.18, a PEG ratio of 1.49 and a beta of 0.82. The company’s 50-day moving average is $23.03 and its two-hundred day moving average is $23.60.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same quarter in the prior year, the firm earned $0.21 EPS. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. Equities analysts anticipate that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Van Berkom & Associates Inc. grew its position in shares of Privia Health Group by 30.1% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after buying an additional 873,344 shares during the period. Vanguard Group Inc. boosted its stake in Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after acquiring an additional 607,447 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Privia Health Group by 139.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after acquiring an additional 489,866 shares in the last quarter. Algert Global LLC grew its holdings in Privia Health Group by 277.4% in the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock worth $12,059,000 after purchasing an additional 355,966 shares during the period. Finally, Freestone Grove Partners LP grew its holdings in Privia Health Group by 40.6% in the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after purchasing an additional 350,194 shares during the period. 94.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on PRVA. JPMorgan Chase & Co. raised their price target on shares of Privia Health Group from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of Privia Health Group in a research report on Monday, December 29th. BMO Capital Markets started coverage on Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Stephens reaffirmed an “overweight” rating and issued a $32.00 price objective on shares of Privia Health Group in a research note on Thursday, December 4th. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.